Remotely adjustable gastric banding device

Information

  • Patent Grant
  • 8845513
  • Patent Number
    8,845,513
  • Date Filed
    Thursday, March 3, 2011
    13 years ago
  • Date Issued
    Tuesday, September 30, 2014
    10 years ago
Abstract
A remotely controllable gastric banding device (10) for placement around the stomach of a patient for the treatment of obesity. The device (10) comprises a gastric band (10) having an inflatable chamber (16) for adjusting the inner circumference of the band (10), a pressurized reservoir (20) with a valve (31) for providing fluid to inflate the inflation chamber (16), a valve (32) for releasing fluid from the inflatable chamber (16), and a controller (41) for controlling the valves (31, 32). The controller (41) is remotely controllable from outside the patient.
Description
FIELD OF THE INVENTION

The present invention relates generally to an apparatus for remotely adjusting the volume in the inflatable portion of a surgically implanted gastric band encircling the stomach. A method for treating morbid obesity utilizing a remotely adjustable gastric banding device is also disclosed.


BACKGROUND OF THE INVENTION

A belt-like gastric band for encircling the stomach to control morbid obesity is disclosed by Vincent in U.S. Pat. No. 5,601,604, incorporated herein by reference. The band comprises a belt that can be passed around the stomach and locked into an encircling position in order to create a stoma opening within the stomach. An adjustable portion of the band comprises an inflatable member which permits fine adjustment of the stoma opening after the stoma is created by locking the band in place.


The gastric banding procedure may involve placement of a calibrating apparatus in the stomach to position the stoma and size the pouch created above the stoma. The gastric band is fastened in position about the stomach to prevent slippage, usually by gastro-gastric sutures.


The stoma opening may be adjusted by injecting or withdrawing a fluid into or from an inflatable member, which is preferably coextensive with a portion of the inner stomach-contacting surface of the band. The means for injecting the fluid into the inflatable member usually comprises a fill port located beneath the skin that can be accessed extracorporeally by transdermal injection. Thus, following implantation, the gastric band can be adjusted to enlarge or reduce the stoma as required.


A potential disadvantage of prior art gastric bands is the difficulty in finely adjusting the stoma created by the implanted band. For example, the fill port located beneath the skin can be difficult to locate precisely. In addition, the fill procedure requires an invasive transdermal injection to adjust the band. Hence, repeated adjustments may be painful or worrisome to the patient. Moreover, exposure to x-rays may be required to facilitate location of the port. It would therefore be desirable to provide a band having an inflatable member that can be easily, precisely, and readily adjusted remotely, without the need to undergo an invasive procedure or radiographic exposure.


To address this problem, several prior art remote control gastric banding devices have been proposed. Klaiber et al. (U.S. Pat. No. 5,938,669) discloses a radio controlled gastric band adjusted by means of an electric pump and a balancing reservoir. Forsell (U.S. Pat. No. 6,210,347) discloses a remotely controlled and powered gastric band adjusted by a motorized mechanical or hydraulic means. Each of these proposed devices operates by pumping fluid to or from the gastric band. Unfortunately, because of their energy requirements, these devices pose problems for practical use. These devices are also not suitable for use with existing gastric banding systems, such as that disclosed by Vincent.


Recent developments in implantable drug delivery devices have shown that small, reliable, and energy-efficient implantable devices are feasible.


Drug delivery devices currently exist in which drugs are administered periodically or continuously to a patient having an implanted device by applying pressure from a pressurized reservoir and opening an outlet valve to allow a pressure differential to cause a flow of the drug. For example, Malamud et al. (U.S. Pat. No. 5,928,195) discloses a remotely controlled drug delivery device suitable for implantation in a body cavity. A pressurized gas chamber presses upon a drug storage chamber thereby administering a dose of the drug when a valve is remotely opened.


Similarly, Arzbaecher (U.S. Pat. No. 5,607,418) discloses an implantable drug apparatus having nested deformable chambers with the outer chamber being pressurized. The pressure from the outer pressurized chamber forces the drug from a reservoir chamber into an inner dispensing chamber. A remotely controlled valve is used to administer a dose of the drug from the dispensing chamber.


Further, Haller et al. (U.S. Pat. No. 6,203,523) discloses an implantable drug infusion device having a flow regulating mechanism that permits the flow rate to be independent of reservoir pressure. Some of the tradeoffs between “passive” (pressurized reservoir-based) devices and “active” (pump-based) devices are discussed in Haller, as follows.


Active drug or programmable infusion devices feature a pump or a metering system to deliver the drug into the patient's system. An example of such an active drug infusion device currently available is the Medtronic SynchroMed™ programmable pump. Such pumps typically include a drug reservoir, a peristaltic pump to pump out the drug from the reservoir, and a catheter port to transport the pumped out drug from the reservoir via the pump to a patient's anatomy. Such devices also typically include a battery to power the pump as well as an electronic module to control the flow rate of the pump. The Medtronic SynchroMed™ pump further includes an antenna to permit the remote programming of the pump. Needless to say, in view of these various components, the cost as well as the size of active drug infusion devices is greater than desired.


Passive drug infusion devices, in contrast, do not feature a pump, but rather rely upon a pressurized drug reservoir to deliver the drug. Thus such devices tend to be both smaller as well as cheaper as compared to active devices. An example of such a device includes the Medtronic IsoMed™ This device delivers the drug into the patient through the force provided by a pressurized reservoir. In particular, this reservoir is pressurized with a drug to between 20 to 40 psi (1.3 to 2.5 bar) and is used to deliver the drug into the patient's system. Typically the flow path of the drug from the reservoir to the patient includes a flow restrictor, which permits a constant flow rate. The flow rate, however, is only constant, if the pressure difference between reservoir and patient does not change. Factors that could impact this pressure difference include temperature, pressure-volume dependence of reservoir and altitude, among others. The selected pressure for the reservoir is thus typically quite high, so that absolute pressure changes only cause small and acceptable errors in flow rate. This also requires, however, the drug to be injected into the reservoir using still higher pressure. This is often a very difficult to achieve using a hand operated syringe.


The foregoing demonstrates a need for a practical, accurate and easy means of remotely adjusting an implanted gastric band.


OBJECTS OF THE INVENTION

It is therefore an object of the present invention to provide a practical, accurate and efficient means for remotely adjusting an implanted gastric band.


It is another object of the present invention to remotely adjust an implanted gastric band having an inflatable member.


It is yet another object of the invention to provide a remote control means suitable for use with existing gastric banding devices and technology.


Still another an object of the present invention is to minimize device complexity for an implanted remotely adjustable gastric banding device to ensure maximum device longevity/durability, in light of the fact that repair would require additional surgery.


Various other objects, advantages and features of the present invention will become readily apparent from the ensuing detailed description and the novel features will be particularly pointed out in the appended claims.


SUMMARY

The present invention applies recent developments in implantable drug delivery device technology to the field of gastric banding.


A preferred embodiment of the invention provides a gastric banding device for treatment of morbid obesity. The device has a gastric band suited for laparoscopic placement around the stomach of a patient to form an adjustable stoma opening. The gastric band has an inflatable chamber for adjusting the inner circumference of the band. The inflatable chamber is preferably substantially coextensive with an inner stomach-facing surface of the gastric band. The inflatable member does not wrinkle or fold when adjusted, thereby presenting a substantially smooth contour along the inner circumference. A fluid-filled pressurized reservoir provides a source of fluid to inflate the inflation chamber of the gastric band. First and second valves control the flow between the pressurized reservoir, the inflatable chamber, and an unpressurized or negatively pressurized outlet. A controller is used to control the valves, thereby regulating the volume change in the inflatable chamber to adjust the inner circumference of the band. The controller is remotely controllable from outside of the patient.


Other aspects of the invention include a remote control for remotely transmitting control signals to the controller, a receiver for receiving control signals from the remote control, and a power source for providing power to the controller and the valves. The power source may be an induction coil. The power source may also be a battery or capacitor charged by a piezoelectric device which converts body motion into electrical energy.


In a method according to the invention, a remotely adjustable gastric banding system may be use for the treatment of obesity. The method comprises the steps of implanting a gastric band, preferably laparoscopically, around the stomach of the patient to create a stoma; remotely transmitting control signals from outside of the patient to a controller of the implanted gastric banding device; and actuating a first valve, between a pressurized reservoir and an inflatable chamber, and/or a second valve, between the inflatable chamber and an outlet, on the basis of the control signals received by the controller to increase or decrease the fluid volume in the inflatable chamber, thereby adjusting the inner circumference of the band to adjust the stoma.





BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings in which:



FIG. 1 is a perspective view of a laparoscopically implantable gastric band, which may be used in the present invention, fastened in an encircling position and partially inflated;



FIG. 2 is a side view of the gastric band shown in FIG. 1; and



FIG. 3 is a schematic diagram showing a remotely controlled fluid distribution system for a gastric band according to the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention combines the implantable drug delivery device technology discussed above with gastric banding technology. The preferred embodiments of the apparatus and method according to the present invention will be described with reference to the accompanying drawings.


Referring to FIG. 1, a gastric band for use with the present invention is disclosed in Vincent (U.S. Pat. No. 5,601,604). This compatible gastric band, indicated as reference numeral 10, has a body portion 11 with an inner stomach-facing surface 15. The body portion 11 has a head end 12 and a tail end or “belt” 13. A fill tube 14, which is generally a tube having a single lumen coextensive therewith, is in fluid communication with an inflatable chamber 16 on the inner surface 15 of the band body 11. Preferably, the inflatable portion 16 is substantially coextensive with the inner surface 15 of the body portion 11. The central lumen of the fill tube 14 is in fluid communication with inflatable chamber 16. The head end 12 of the body portion 11 has a “buckle” 19 through which the tail end of “belt” 13 is inserted and locked in place in use. Head end 12 may be provided with a pull tab 18 for use in locking the band in place about the stomach.


In use, the gastric band is placed in an encircling position around the stomach and locked in place as shown in FIG. 2. (In FIG. 2, the stomach is omitted for clarity.) This is accomplished by introducing the gastric band 10 through a laparoscopic cannula (not shown) in a patient's abdominal cavity. Laparoscopic placement consists of blunt dissection below the gastro-esophageal junction followed by placement of the band. The end of the fill tube 14 is passed through the dissected path around the upper stomach, and the tail end or belt 13 is passed through buckle 19, so that the belt and buckle lock in place. A laparoscopic closure tool, such as that disclosed by Coe and Vincent in U.S. Pat. No. 5,658,298, incorporated herein by reference, may be used. Hence, with the gastric band affixed in an encircling position around the stomach, a new stoma (opening) is created within the stomach. After the band is secured in position, the size of the stoma may be adjusted by adding fluid to or withdrawing fluid from the inflatable member 16 to bring the stoma opening to the desired size. The inflatable member or chamber 16 is preferably coextensive with the inner stomach-facing surface 15 of the band between the head end 12 and the tail end 13. The interior of the adjustable chamber 16 is in fluid communication with a fluid reservoir (not shown) by means of the central lumen of the fill tube 14, as with prior art adjustable gastric bands. The inflatable member 16 is gradually inflated or deflated with saline or other biologically compatible fluid via the fluid reservoir such that the inflatable member 16 presses on and constricts the stomach wall or other tissue underlying the band. This results in the decrease or increase of the size of the stomach opening directly inside the encircling band.



FIG. 3 is a schematic diagram depicting a remotely adjustable gastric band 100 constructed in accordance with the present invention. In FIG. 3, the pressure in the inflatable member 16 of the remote gastric banding system 100 is represented by the band inflation pressure P2. Pressure P2 is regulated by an inlet valve 31 and an outlet valve 32. Pressurized reservoir 20, having a pressure P1, is connected to the inflatable chamber 16 through inlet valve 31 and tube 21, which corresponds to fill tube 14 in FIG. 2. Pressurized reservoir 20 is analogous to the pressurized reservoirs discussed above in relation to implantable drug delivery devices. This reservoir may be connected to the fill tube 21 as shown, or it may be incorporated into the body 11 of the band itself, e.g. on the outer surface, opposite the inner stomach-facing surface 15, and communicate directly with inflatable chamber 16 though inlet valve 21. Inflatable member 16 is also connected to outlet 23, having a pressure P3, through tube 22 and valve 32. Outlet 23 may be either a separate waste reservoir as shown in FIG. 3 or the peritoneal cavity of the patient's body. When outlet 23 is a waste reservoir, P3 may be negative. Where pressure outlet 23 is the patient's peritoneal cavity, P3 will be at ambient pressure within the body.


In the present invention, the pressure relationship between reservoir 20, inflatable member 16 and outlet 23 is initially represented by the formula P1>P2>P3. Hence, valve 31 may be used to increase the pressure P2 up to a maximum pressure of P2=P1, thereby inflating inflatable member 16. Similarly, valve 32 may be used to decrease the pressure P2 down to a minimum of P2=P3, thereby deflating inflatable member 16. Thus, by actuating valves 31 and 32, the fluid volume in the inflatable member 16 may be regulated, thereby adjusting the size of the stoma formed by the gastric band.


In the present invention, valves 31 and 32 are controlled by a controller 41. The valves are preferably controlled in accordance with externally transmitted signals (not shown) received by a receiver 42 but may ultimately be controlled by any control system, including internal, mechanical, wired, or the like. The signals are preferably radio frequency (RF) signals transmitted by a remote control device 40 located external to the implanted gastric banding system. Power may be supplied to the receiver, the controller, and/or the valves either from an implanted power source 43 or from an induction coil 43 that receives power from a concentric coil external to the body, as described for instance for hearing aids in Baumann et al. (U.S. Pat. No. 5,279,292), which is hereby incorporated by reference.


The entirety of the remote gastric banding system 100 shown in FIG. 3 may be laparoscopically implanted in the patient. Subsequent adjustment of the band can be simply, quickly, and painlessly performed using a remote control device to remotely inflate/deflate the inflatable portion 16 of the band. The entire system 100 may be removed from the patient if necessary. No permanent anatomical changes should be anticipated.


The remote control device 40 can be in the form of a typical television remote control, a personal computer interfaced device, or any other format. A unique identification code may be assigned to each remotely adjustable gastric band, so that access to and control of the device is restricted. This code may be a PIN code and may also act to prevent accidental adjustment of the band.


The system may be pressurized using a saline solution, or any other biocompatible fluid. If desired, a concentrated saline solution may be used as the inflation medium, thereby allowing water from the patient's body to diffuse into the inflatable member 16 over time and further inflate the band. After repeated adjustments the reservoir 20 may be refilled through an access port (not shown) or replaced altogether. As a backup and safety measure, the system may also allow for inflation/deflation of inflatable member 16 by transdermal injection through a fill port (not shown) as in prior art gastric banding devices.


Because this system uses a pressurized reservoir rather than a mechanical pressurization means (i.e. a pump or screw), the present system is more energy-efficient than those disclosed in the existing remote-controlled adjustable gastric band systems of Klaiber or Forsell (U.S. Pat. Nos. 5,938,669 and 6,210,347). Power is only required when operating the valves 31 and/or 32, and then only for relatively short time intervals.


Alternative embodiments of the present invention may include means for measuring fluid flow through the valves 31 and/or 32, such as a mass flowmeter, to ensure accuracy in adjusting the stoma when inflatable member 16 is inflated or deflated. Also, the controller 41 may be positioned external to the body. An alternate gastric band design might also be used, provided that the inflation medium remains a fluid.


A further embodiment of the present invention is a method of treating obesity using the remotely adjustable gastric banding system disclosed herein. The method includes implanting a gastric band, preferably laparoscopically, around the stomach of the patient to create a stoma; remotely transmitting control signals from outside of the patient to controller 41 of the gastric banding device inside of the patient; and opening and closing valve 31, between pressurized reservoir 20 and inflatable chamber 16, and/or valve 32, between the inflatable chamber and outlet 23, on the basis of the control signals received by controller 23 to increase or decrease the pressure in the inflatable chamber, thereby adjusting the inner circumference of the band to adjust the stoma size.


Although the invention has been particularly shown and described with reference to certain preferred embodiments, it will be readily appreciated by those of ordinary skill in the art that various changes and modifications may be made therein, without departing from the spirit and scope of the invention. It is intended that the claims be interpreted as including the foregoing as well as various other such changes and modifications.

Claims
  • 1. A pressurized inflatable gastric banding system for placement around the stomach of a patient for treating obesity in the patient, comprising: a gastric band constructed to be placed around the stomach of the patient;an inflatable member positioned along an inner surface of the gastric band constructed to adjust an inner circumference of the gastric band, the inflatable member having a pressure P2;a pressurized inlet reservoir selectively coupled to the inflatable member and constructed to contain a fluid, the inlet reservoir having a pressure P1 that remains greater than or equal to the pressure P2;an electrically powered inlet valve in fluid communication with the inlet reservoir and the inflatable member, the inlet valve being connected between the inlet reservoir and the inflatable member;an outlet reservoir selectively coupled to the inflatable member constructed to receive fluid from the inflatable member, the outlet reservoir having a pressure P3 that does not exceed the pressure P2; andan electrically powered outlet valve in fluid communication with the inflatable member and the outlet reservoir, the outlet valve connected between the inflatable member and the outlet reservoir; anda controller, coupled to the inlet valve and the outlet valve, constructed to actuate the inlet valve to release the fluid from the pressurized reservoir to control the flow of the fluid from the reservoir to the inflatable member and to actuate the outlet valve to release the fluid from the inflatable member to control the flow of the fluid from the inflatable member to the outlet reservoir, the controller constructed to be remotely controllable from outside of the patient, wherein the gastric band is constructed to form a smoothly surfaced circle around the stomach of the patient, and wherein the controller is constructed to actuate the inlet valve to fluidly couple only the inlet reservoir to the inflatable member and to actuate the outlet valve to fluidly couple only the outlet reservoir to the inflatable member.
  • 2. The system of claim 1 wherein the inflatable member does not wrinkle or fold when adjusting the inner circumference of the gastric band.
  • 3. The system of claim 2 wherein the gastric band is lockable in the smoothly surfaced circle.
  • 4. The system according to claim 1, wherein the controller is constructed to transmit a control signal to the valves based on an externally transmitted signal.
  • 5. The system according to claim 4, wherein the valves are constructed to receive the control signal.
  • 6. The system according to claim 5, wherein the actuation of the valves is responsive to the received control signal.
  • 7. The system according to claim 6, further including a receiver in communication with the controller, the receiver constructed to receive the externally transmitted signal.
  • 8. An inflatable gastric banding apparatus for placement around the stomach of a patient for treating obesity in the patient, comprising: a gastric band constructed to be positioned around a stomach in a body of the patient, the gastric band having an inflatable chamber;a pressurized inlet fluid reservoir, selectively coupled to the inflatable chamber, constructed to passively provide a fluid to the inflatable chamber for inflating the inflatable chamber;an inlet valve coupled between the inflatable chamber and the inlet fluid reservoir;an outlet reservoir, selectively coupled to the inflatable chamber, constructed to passively receive fluid from the inflatable chamber for deflating the inflatable chamber; andan outlet valve coupled between the inflatable chamber and the outlet reservoir, the inflatable chamber constructed to passively provide the fluid to the outlet reservoir for deflating the inflatable chamber; anda controller constructed to actuate the inlet valve and the outlet valve, and wherein the controller is constructed to actuate the inlet valve to fluidly couple only the inlet reservoir to the inflatable chamber and to actuate the outlet valve to fluidly couple only the outlet reservoir to the inflatable chamber.
  • 9. The apparatus of claim 8 wherein the fluid is a concentrated saline solution.
  • 10. The apparatus of claim 8 wherein the controller is positioned external to the body of the patient.
  • 11. The apparatus of claim 8 wherein the controller actuates the valve wirelessly.
  • 12. The apparatus according to claim 8, wherein the controller is constructed to transmit a control signal to the valves based on an externally transmitted signal.
  • 13. The apparatus according to claim 12, wherein the valves are constructed to receive the control signal.
  • 14. The apparatus according to claim 13, wherein the actuation of the valves is responsive to the received control signal.
  • 15. The apparatus according to claim 14, wherein the controller is communicatively coupled to a receiver, and is constructed to generate the control signal based on communication with the receiver.
  • 16. The apparatus according to claim 8, wherein the inflatable chamber is constructed to receive body fluid from the body of the patient for further inflating the inflatable chamber, and wherein the gastric band is constructed to form a smoothly surfaced circle around the stomach of the patient.
  • 17. The apparatus according to claim 8, wherein the inlet reservoir has a pressure P1 that remains greater than or equal to the pressure P2 and wherein the outlet reservoir has a pressure P3 that does not exceed the pressure P2.
  • 18. A pressurized inflatable gastric banding system for placement around the stomach of a patient for treating obesity in the patient, comprising: a gastric band constructed to be positioned around a stomach in a body of the patient, the gastric band having an inflatable chamber;a pressurized inlet fluid reservoir, selectively coupled to the inflatable chamber, constructed to passively provide a pressurized fluid to the inflatable chamber for inflating the inflatable chamber;an inlet valve coupled between the inflatable chamber and the fluid reservoir;an outlet reservoir, selectively coupled to the inflatable chamber, constructed to passively receive fluid from the inflatable chamber for deflating the inflatable chamber; andan outlet valve coupled between the inflatable chamber and the outlet reservoir, the inflatable chamber constructed to passively provide the fluid to the outlet reservoir for deflating the inflatable chamber; anda controller, coupled to the inlet valve and the outlet valve, constructed to actuate the inlet valve to release the pressurized fluid from the pressurized reservoir to control the flow of the fluid from the reservoir to the inflatable member and to actuate the outlet valve to release the fluid from the inflatable member to control the flow of the fluid from the inflatable member to the outlet reservoir, the controller constructed to be remotely controllable from outside of the patient, and wherein the controller is constructed to actuate the inlet valve to fluidly couple only the inlet reservoir to the inflatable chamber and to actuate the outlet valve to fluidly couple only the outlet reservoir to the inflatable chamber.
RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No. 12/041,547, filed on Mar. 3, 2008, which is a continuation of U.S. application Ser. No. 10/524,864, filed on Jun. 23, 2005, now U.S. Pat. No. 7,338,433, issued on Mar. 4, 2008, which was a National Stage Entry of PCT/US02/25654, filed on Aug. 13, 2002.

US Referenced Citations (526)
Number Name Date Kind
1174814 Brennan et al. Mar 1916 A
1830947 Klingel Nov 1931 A
1999683 Borresen Apr 1935 A
2163048 McKee Jun 1939 A
2339138 Black Jan 1944 A
2405667 Ottesen Aug 1946 A
2438231 Schultz et al. Mar 1948 A
2635907 Heimbuch Apr 1953 A
2714469 Carlson Aug 1955 A
2936980 Rapata May 1960 A
3059645 Hasbrouck et al. Oct 1962 A
3189961 Heller Jun 1965 A
3667081 Burger Jun 1972 A
3840018 Heifetz Oct 1974 A
3955834 Ahlrot May 1976 A
4053176 Hilbush Oct 1977 A
4118805 Reimels Oct 1978 A
4133315 Berman et al. Jan 1979 A
4157713 Clarey Jun 1979 A
4176412 Peterson Dec 1979 A
4236521 Lauterjung Dec 1980 A
4271827 Angelchick Jun 1981 A
4299012 Oetiker Nov 1981 A
4340083 Cummins Jul 1982 A
4399809 Baro et al. Aug 1983 A
4408597 Tenney, Jr. et al. Oct 1983 A
4417567 Trick Nov 1983 A
4424208 Wallace et al. Jan 1984 A
4442153 Meltsch Apr 1984 A
4450375 Siegal May 1984 A
4485805 Foster, Jr. Dec 1984 A
4492004 Oetiker Jan 1985 A
4551862 Haber Nov 1985 A
4558699 Bashour Dec 1985 A
4559699 Owen et al. Dec 1985 A
4582640 Smestad et al. Apr 1986 A
4582865 Balazs et al. Apr 1986 A
4592339 Kuzmak et al. Jun 1986 A
4592355 Antebi Jun 1986 A
4601713 Fuqua Jul 1986 A
4667672 Romanowski May 1987 A
4671351 Rappe Jun 1987 A
4693695 Cheng Sep 1987 A
4694827 Weiner et al. Sep 1987 A
4696288 Kuzmak et al. Sep 1987 A
4708140 Baron Nov 1987 A
4716154 Malson et al. Dec 1987 A
4753086 Schmidt Jun 1988 A
4760837 Petit Aug 1988 A
4803075 Wallace et al. Feb 1989 A
4881939 Newman Nov 1989 A
4883467 Franetzki et al. Nov 1989 A
4886787 de Belder et al. Dec 1989 A
4896787 Delamour et al. Jan 1990 A
4915690 Cone et al. Apr 1990 A
4925446 Garay et al. May 1990 A
4944487 Holtermann Jul 1990 A
4944659 Labbe et al. Jul 1990 A
4958791 Nakamura Sep 1990 A
4969899 Cox, Jr. Nov 1990 A
4976735 Griffith et al. Dec 1990 A
4994019 Fernandez et al. Feb 1991 A
5045060 Melsky et al. Sep 1991 A
5074868 Kuzmak Dec 1991 A
5084061 Gau et al. Jan 1992 A
5091171 Yu et al. Feb 1992 A
5116652 Alzner May 1992 A
5120313 Elftman Jun 1992 A
5143724 Leshchiner et al. Sep 1992 A
5152770 Bengmark et al. Oct 1992 A
5160338 Vincent Nov 1992 A
5188609 Bayless et al. Feb 1993 A
5224494 Enhorning Jul 1993 A
5226429 Kuzmak Jul 1993 A
5246456 Wilkinson Sep 1993 A
5246698 Leshchiner et al. Sep 1993 A
5259399 Brown Nov 1993 A
5326349 Baraff Jul 1994 A
5343894 Frisch et al. Sep 1994 A
5356883 Kuo et al. Oct 1994 A
5360445 Goldowsky Nov 1994 A
5391156 Hildwein et al. Feb 1995 A
5399351 Leshchiner et al. Mar 1995 A
5449363 Brust et al. Sep 1995 A
5449368 Kuzmak Sep 1995 A
5458568 Racchini et al. Oct 1995 A
5509888 Miller Apr 1996 A
5531716 Luzio et al. Jul 1996 A
5535752 Halperin et al. Jul 1996 A
5554113 Novak et al. Sep 1996 A
5562714 Grevious Oct 1996 A
5601604 Vincent Feb 1997 A
5607418 Arzbaecher Mar 1997 A
5633001 Agerup May 1997 A
5653718 Yoon Aug 1997 A
5658298 Vincent et al. Aug 1997 A
5676162 Larson, Jr. et al. Oct 1997 A
5695504 Gifford, III et al. Dec 1997 A
5704893 Timm Jan 1998 A
5713911 Racenet et al. Feb 1998 A
5733257 Sternby Mar 1998 A
5748200 Funahashi May 1998 A
5766232 Grevious et al. Jun 1998 A
5769877 Barreras, Sr. Jun 1998 A
5785295 Tsai Jul 1998 A
5817113 Gifford, III et al. Oct 1998 A
5827529 Ono et al. Oct 1998 A
5833698 Hinchliffe et al. Nov 1998 A
5861014 Familoni Jan 1999 A
RE36176 Kuzmak Mar 1999 E
5886042 Yu et al. Mar 1999 A
5904697 Gifford, III et al. May 1999 A
5910149 Kuzmak Jun 1999 A
5928195 Malamud et al. Jul 1999 A
5938669 Klaiber et al. Aug 1999 A
5944696 Bayless et al. Aug 1999 A
5944751 Laub Aug 1999 A
5993473 Chan et al. Nov 1999 A
6013679 Kuo et al. Jan 2000 A
6024340 Lazarus et al. Feb 2000 A
6024704 Meador et al. Feb 2000 A
6048309 Flom et al. Apr 2000 A
6067991 Forsell May 2000 A
6074341 Anderson et al. Jun 2000 A
6074378 Mouri et al. Jun 2000 A
6083249 Familoni Jul 2000 A
6090131 Daley Jul 2000 A
6102678 Peclat Aug 2000 A
6102922 Jakobsson et al. Aug 2000 A
6171321 Gifford, III et al. Jan 2001 B1
6193734 Bolduc et al. Feb 2001 B1
6203523 Haller et al. Mar 2001 B1
6210345 Van Brunt Apr 2001 B1
6210347 Forsell Apr 2001 B1
6221024 Miesel Apr 2001 B1
6224857 Romeo et al. May 2001 B1
6306088 Krausman et al. Oct 2001 B1
6327503 Familoni Dec 2001 B1
6371965 Gifford, III et al. Apr 2002 B2
6372494 Naughton et al. Apr 2002 B1
6383218 Sourdile et al. May 2002 B1
6383219 Telandro et al. May 2002 B1
6387105 Gifford, III et al. May 2002 B1
6417750 Shon Jul 2002 B1
6418934 Chin Jul 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6432040 Meah Aug 2002 B1
6439539 Powell Aug 2002 B1
6443957 Addis Sep 2002 B1
6443965 Gifford, III et al. Sep 2002 B1
6450173 Forsell Sep 2002 B1
6450946 Forsell Sep 2002 B1
6451034 Gifford, III et al. Sep 2002 B1
6453907 Forsell Sep 2002 B1
6454699 Forsell Sep 2002 B1
6454700 Forsell Sep 2002 B1
6454701 Forsell Sep 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6457801 Fish et al. Oct 2002 B1
6460543 Forsell Oct 2002 B1
6461293 Forsell Oct 2002 B1
6463935 Forsell Oct 2002 B1
6464628 Forsell Oct 2002 B1
6470892 Forsell Oct 2002 B1
6474584 Ekich Nov 2002 B2
6475136 Forsell Nov 2002 B1
6485496 Suyker et al. Nov 2002 B1
6491704 Gifford, III et al. Dec 2002 B2
6491705 Gifford, III et al. Dec 2002 B2
6511490 Robert Jan 2003 B2
6517556 Monassevitch Feb 2003 B1
6527701 Sayet et al. Mar 2003 B1
6547801 Dargent et al. Apr 2003 B1
6565582 Gifford, III et al. May 2003 B2
6579301 Bales et al. Jun 2003 B1
6601604 Cooper Aug 2003 B1
6615084 Cigaina Sep 2003 B1
6627620 Nielsen Sep 2003 B1
6630486 Royer Oct 2003 B1
6632239 Snyder et al. Oct 2003 B2
6646628 Shirochi et al. Nov 2003 B2
6676674 Dudai Jan 2004 B1
6685668 Cho et al. Feb 2004 B1
6685963 Taupin et al. Feb 2004 B1
6691047 Fredricks Feb 2004 B1
6715731 Post et al. Apr 2004 B1
6729600 Mattes et al. May 2004 B2
6754527 Stroebel et al. Jun 2004 B2
6767924 Yu et al. Jul 2004 B2
6811136 Eberhardt et al. Nov 2004 B2
6820651 Seuret et al. Nov 2004 B2
6834201 Gillies et al. Dec 2004 B2
6871090 He et al. Mar 2005 B1
6889086 Mass et al. May 2005 B2
6916326 Benchetrit Jul 2005 B2
6921819 Piron et al. Jul 2005 B2
6924273 Pierce Aug 2005 B2
6940467 Fisher et al. Sep 2005 B2
6966875 Longobardi Nov 2005 B1
7017583 Forsell Mar 2006 B2
7021147 Subramanian et al. Apr 2006 B1
7037344 Kagan et al. May 2006 B2
7040349 Moler et al. May 2006 B2
7054690 Imran May 2006 B2
7058434 Wang et al. Jun 2006 B2
7060080 Bachmann Jun 2006 B2
7066486 Lee Jun 2006 B2
7118526 Egle Oct 2006 B2
7119062 Alvis et al. Oct 2006 B1
7128750 Stergiopulos Oct 2006 B1
7144400 Byrum et al. Dec 2006 B2
7172607 Hofle et al. Feb 2007 B2
7177693 Starkebsum Feb 2007 B2
7191007 Desai et al. Mar 2007 B2
7204821 Clare et al. Apr 2007 B1
7223239 Schulze et al. May 2007 B2
7238191 Bachmann Jul 2007 B2
7240607 Fish Jul 2007 B2
7255675 Gertner et al. Aug 2007 B2
7263405 Boveja et al. Aug 2007 B2
7282023 Frering Oct 2007 B2
7288064 Boustani et al. Oct 2007 B2
7297103 Jarsaillon et al. Nov 2007 B2
7299082 Feldman et al. Nov 2007 B2
7310557 Maschino et al. Dec 2007 B2
7311716 Byrun Dec 2007 B2
7311717 Egle Dec 2007 B2
7314443 Jordan et al. Jan 2008 B2
7314636 Caseres et al. Jan 2008 B2
7338433 Coe Mar 2008 B2
7340306 Barrett et al. Mar 2008 B2
7351198 Byrum et al. Apr 2008 B2
7351240 Hassler, Jr. et al. Apr 2008 B2
7364542 Jambor et al. Apr 2008 B2
7367340 Nelson et al. May 2008 B2
7367937 Jambor et al. May 2008 B2
7374565 Hassler, Jr. et al. May 2008 B2
7390294 Hassler, Jr. Jun 2008 B2
7396353 Lorenzen et al. Jul 2008 B2
7416528 Crawford et al. Aug 2008 B2
7457668 Cancel et al. Nov 2008 B2
7481763 Hassler, Jr. et al. Jan 2009 B2
7500944 Byrum et al. Mar 2009 B2
7502649 Ben-Haim et al. Mar 2009 B2
7530943 Lechner May 2009 B2
7594885 Byrum Sep 2009 B2
7599743 Hassler, Jr. et al. Oct 2009 B2
7599744 Giordano et al. Oct 2009 B2
7601162 Hassler, Jr. et al. Oct 2009 B2
7615001 Jambor et al. Nov 2009 B2
7618365 Jambor et al. Nov 2009 B2
7658196 Ferreri et al. Feb 2010 B2
7670279 Gertner Mar 2010 B2
7699770 Hassler, Jr. et al. Apr 2010 B2
7712470 Gertner May 2010 B2
7727141 Hassler, Jr. et al. Jun 2010 B2
7741476 Lebreton Jun 2010 B2
7758493 Gingras Jul 2010 B2
7763039 Ortiz et al. Jul 2010 B2
7766815 Ortiz Aug 2010 B2
7771439 Griffiths Aug 2010 B2
7775215 Hassler, Jr. et al. Aug 2010 B2
7775966 Dlugos et al. Aug 2010 B2
7775967 Gertner Aug 2010 B2
7794386 Brooks Sep 2010 B2
7811298 Birk Oct 2010 B2
7824422 Benchetrit Nov 2010 B2
7828813 Mouton Nov 2010 B2
7832407 Gertner Nov 2010 B2
7841978 Gertner Nov 2010 B2
7844342 Dlugos, Jr. et al. Nov 2010 B2
7862502 Pool et al. Jan 2011 B2
7879068 Dlugos et al. Feb 2011 B2
7951067 Byrum et al. May 2011 B2
20010011543 Forsell Aug 2001 A1
20020072780 Foley Jun 2002 A1
20020091395 Gabbay Jul 2002 A1
20020095181 Beyar Jul 2002 A1
20020098097 Singh Jul 2002 A1
20020139208 Yatskov Oct 2002 A1
20020183765 Adams Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20020198548 Robert Dec 2002 A1
20030014003 Gertner Jan 2003 A1
20030019498 Forsell Jan 2003 A1
20030045775 Forsell Mar 2003 A1
20030045902 Weadock Mar 2003 A1
20030060873 Gertner et al. Mar 2003 A1
20030066536 Forsell Apr 2003 A1
20030073880 Polsky et al. Apr 2003 A1
20030093157 Casares et al. May 2003 A1
20030100910 Gifford, III et al. May 2003 A1
20030120288 Benchetrit Jun 2003 A1
20030148995 Piron et al. Aug 2003 A1
20030158564 Benchetrit Aug 2003 A1
20030158569 Wazne Aug 2003 A1
20030181890 Schulze et al. Sep 2003 A1
20030181917 Gertner Sep 2003 A1
20030191433 Prentiss Oct 2003 A1
20030208212 Cigaina Nov 2003 A1
20040000843 East Jan 2004 A1
20040044332 Stergiopulos Mar 2004 A1
20040049209 Benchetrit Mar 2004 A1
20040059393 Policker et al. Mar 2004 A1
20040068847 Belisle et al. Apr 2004 A1
20040106899 McMichael et al. Jun 2004 A1
20040133219 Forsell Jul 2004 A1
20040147816 Policker et al. Jul 2004 A1
20040148034 Kagan et al. Jul 2004 A1
20040153106 Dudai Aug 2004 A1
20040162595 Foley Aug 2004 A1
20040215159 Forsell Oct 2004 A1
20040230137 Mouton Nov 2004 A1
20040254536 Conlon et al. Dec 2004 A1
20040254537 Conlon et al. Dec 2004 A1
20040260319 Egle Dec 2004 A1
20040267288 Byrum et al. Dec 2004 A1
20040267291 Byrum et al. Dec 2004 A1
20040267292 Byrum et al. Dec 2004 A1
20040267293 Byrum et al. Dec 2004 A1
20040267377 Egle Dec 2004 A1
20050002984 Byrum et al. Jan 2005 A1
20050038484 Knudson et al. Feb 2005 A1
20050038498 Dubrow et al. Feb 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050070934 Tanaka et al. Mar 2005 A1
20050070937 Jambor et al. Mar 2005 A1
20050100779 Gertner May 2005 A1
20050104457 Jordan et al. May 2005 A1
20050119672 Benchetrit Jun 2005 A1
20050119674 Gingras Jun 2005 A1
20050131383 Chen et al. Jun 2005 A1
20050131485 Knudson et al. Jun 2005 A1
20050136122 Sadozai et al. Jun 2005 A1
20050142152 Leshchiner et al. Jun 2005 A1
20050143765 Bachmann et al. Jun 2005 A1
20050143766 Bachmann et al. Jun 2005 A1
20050154274 Jarsaillon et al. Jul 2005 A1
20050171568 Duffy Aug 2005 A1
20050183730 Byrum Aug 2005 A1
20050192531 Birk Sep 2005 A1
20050192601 Demarais Sep 2005 A1
20050192629 Saadat et al. Sep 2005 A1
20050216042 Gertner Sep 2005 A1
20050226936 Agerup Oct 2005 A1
20050228415 Gertner Oct 2005 A1
20050228504 Demarais Oct 2005 A1
20050240155 Conlon Oct 2005 A1
20050240156 Conlon Oct 2005 A1
20050240279 Kagan et al. Oct 2005 A1
20050244288 O'Neil Nov 2005 A1
20050250979 Coe Nov 2005 A1
20050251181 Bachmann Nov 2005 A1
20050251182 Bachmann Nov 2005 A1
20050267406 Hassler, Jr. Dec 2005 A1
20050267500 Hassler, Jr. Dec 2005 A1
20050267533 Gertner Dec 2005 A1
20050271729 Wang Dec 2005 A1
20050277899 Conlon et al. Dec 2005 A1
20050283041 Egle Dec 2005 A1
20050288739 Hassler, Jr. et al. Dec 2005 A1
20050288740 Hassler, Jr. et al. Dec 2005 A1
20060015138 Gertner Jan 2006 A1
20060020298 Camilleri et al. Jan 2006 A1
20060041183 Massen et al. Feb 2006 A1
20060074439 Garner et al. Apr 2006 A1
20060074473 Gertner Apr 2006 A1
20060089571 Gertner Apr 2006 A1
20060122147 Wohlrab Jun 2006 A1
20060142700 Sobelman et al. Jun 2006 A1
20060142790 Gertner Jun 2006 A1
20060161139 Levine et al. Jul 2006 A1
20060161186 Hassler, Jr. et al. Jul 2006 A1
20060167531 Gertner et al. Jul 2006 A1
20060173238 Starkebaum Aug 2006 A1
20060173424 Conlon Aug 2006 A1
20060183967 Lechner Aug 2006 A1
20060189887 Hassler, Jr. et al. Aug 2006 A1
20060189888 Hassler, Jr. et al. Aug 2006 A1
20060189889 Gertner Aug 2006 A1
20060194758 Lebreton Aug 2006 A1
20060195139 Gertner Aug 2006 A1
20060197412 Rasmussen Sep 2006 A1
20060199997 Hassler, Jr. et al. Sep 2006 A1
20060211912 Dlugos et al. Sep 2006 A1
20060211913 Dlugos et al. Sep 2006 A1
20060211914 Hassler, Jr. et al. Sep 2006 A1
20060212051 Snyder et al. Sep 2006 A1
20060212053 Gertner Sep 2006 A1
20060235448 Roslin et al. Oct 2006 A1
20060246137 Hermitte et al. Nov 2006 A1
20060247721 Maschino et al. Nov 2006 A1
20060247722 Maschino et al. Nov 2006 A1
20060252982 Hassler, Jr. Nov 2006 A1
20060252983 Lembo et al. Nov 2006 A1
20060257488 Hubbard Nov 2006 A1
20060264699 Gertner Nov 2006 A1
20060276812 Hill et al. Dec 2006 A1
20060293627 Byrum et al. Dec 2006 A1
20070015954 Dlugos Jan 2007 A1
20070015955 Tsonton Jan 2007 A1
20070015956 Crawford et al. Jan 2007 A1
20070016231 Jambor et al. Jan 2007 A1
20070016262 Gross et al. Jan 2007 A1
20070027356 Ortiz Feb 2007 A1
20070027358 Gertner et al. Feb 2007 A1
20070044655 Fish Mar 2007 A1
20070077292 Pinsky Apr 2007 A1
20070078476 Hull, Sr. et al. Apr 2007 A1
20070125826 Shelton Jun 2007 A1
20070156013 Birk Jul 2007 A1
20070167672 Dlugos et al. Jul 2007 A1
20070167982 Gertner et al. Jul 2007 A1
20070173685 Jambor et al. Jul 2007 A1
20070173888 Gertner et al. Jul 2007 A1
20070179335 Gertner et al. Aug 2007 A1
20070185373 Tsonton Aug 2007 A1
20070185462 Byrum Aug 2007 A1
20070213836 Paganon Sep 2007 A1
20070218083 Brooks Sep 2007 A1
20070232848 Forsell Oct 2007 A1
20070232849 Gertner Oct 2007 A1
20070233170 Gertner Oct 2007 A1
20070235083 Dlugos Oct 2007 A1
20070243227 Gertner Oct 2007 A1
20070250085 Bachmann et al. Oct 2007 A1
20070250086 Wiley et al. Oct 2007 A1
20070255335 Herbert et al. Nov 2007 A1
20070255336 Herbert et al. Nov 2007 A1
20070265598 Karasik Nov 2007 A1
20070265645 Birk et al. Nov 2007 A1
20070265646 McCoy et al. Nov 2007 A1
20070293716 Baker et al. Dec 2007 A1
20070298005 Thibault Dec 2007 A1
20080009680 Hassler, Jr. Jan 2008 A1
20080015406 Dlugos et al. Jan 2008 A1
20080015501 Gertner Jan 2008 A1
20080027269 Gertner Jan 2008 A1
20080027469 Bachmann Jan 2008 A1
20080071306 Gertner Mar 2008 A1
20080097496 Chang et al. Apr 2008 A1
20080108862 Jordan et al. May 2008 A1
20080147002 Gertner Jun 2008 A1
20080161717 Gertner Jul 2008 A1
20080161875 Stone Jul 2008 A1
20080167647 Gertner Jul 2008 A1
20080167648 Gertner Jul 2008 A1
20080172072 Pool et al. Jul 2008 A1
20080188766 Gertner Aug 2008 A1
20080195092 Kim et al. Aug 2008 A1
20080208240 Paz Aug 2008 A1
20080221598 Dlugos et al. Sep 2008 A1
20080243071 Quijano et al. Oct 2008 A1
20080249806 Dlugos et al. Oct 2008 A1
20080250340 Dlugos et al. Oct 2008 A1
20080250341 Dlugos et al. Oct 2008 A1
20080255403 Voegele et al. Oct 2008 A1
20080255414 Voegele et al. Oct 2008 A1
20080255425 Voegele et al. Oct 2008 A1
20080255459 Voegele et al. Oct 2008 A1
20080255537 Voegele et al. Oct 2008 A1
20080275294 Gertner Nov 2008 A1
20080275295 Gertner Nov 2008 A1
20080275484 Gertner Nov 2008 A1
20080281347 Gertner Nov 2008 A1
20080287969 Tsonton et al. Nov 2008 A1
20080287974 Widenhouse et al. Nov 2008 A1
20080287976 Weaner et al. Nov 2008 A1
20080300618 Gertner Dec 2008 A1
20080319435 Rioux et al. Dec 2008 A1
20090054914 Lechner Feb 2009 A1
20090062825 Pool et al. Mar 2009 A1
20090062826 Steffen Mar 2009 A1
20090082793 Birk Mar 2009 A1
20090118572 Lechner May 2009 A1
20090149874 Ortiz et al. Jun 2009 A1
20090157106 Marcotte et al. Jun 2009 A1
20090157107 Kierath et al. Jun 2009 A1
20090157113 Marcotte et al. Jun 2009 A1
20090171375 Coe et al. Jul 2009 A1
20090171378 Coe et al. Jul 2009 A1
20090171379 Coe et al. Jul 2009 A1
20090187202 Ortiz et al. Jul 2009 A1
20090192404 Ortiz et al. Jul 2009 A1
20090192415 Ortiz et al. Jul 2009 A1
20090192533 Dlugos, Jr. et al. Jul 2009 A1
20090192534 Ortiz et al. Jul 2009 A1
20090192541 Ortiz et al. Jul 2009 A1
20090198261 Schweikert Aug 2009 A1
20090202387 Dlugos, Jr. et al. Aug 2009 A1
20090204131 Ortiz et al. Aug 2009 A1
20090204132 Ortiz et al. Aug 2009 A1
20090209995 Byrum et al. Aug 2009 A1
20090216255 Coe et al. Aug 2009 A1
20090220176 Fusco Sep 2009 A1
20090222031 Axelsson Sep 2009 A1
20090222065 Dlugos, Jr. et al. Sep 2009 A1
20090228063 Dlugos, Jr. et al. Sep 2009 A1
20090228072 Coe et al. Sep 2009 A1
20090270904 Birk et al. Oct 2009 A1
20090306462 Lechner Dec 2009 A1
20100010291 Birk et al. Jan 2010 A1
20100049224 Vargas Feb 2010 A1
20100087843 Bertolote et al. Apr 2010 A1
20100099945 Birk et al. Apr 2010 A1
20100100079 Berkcan Apr 2010 A1
20100145378 Gertner Jun 2010 A1
20100152532 Marcotte Jun 2010 A1
20100168508 Gertner Jul 2010 A1
20100185049 Birk et al. Jul 2010 A1
20100191265 Lau et al. Jul 2010 A1
20100191271 Lau et al. Jul 2010 A1
20100204647 Gertner Aug 2010 A1
20100204723 Gertner Aug 2010 A1
20100217071 Ricol Aug 2010 A1
20100226988 Lebreton Sep 2010 A1
20100228080 Tavori et al. Sep 2010 A1
20100234682 Gertner Sep 2010 A1
20100249803 Griffiths Sep 2010 A1
20100280310 Raven Nov 2010 A1
20100305397 Birk et al. Dec 2010 A1
20100312046 Lau et al. Dec 2010 A1
20100312147 Gertner Dec 2010 A1
20100324358 Birk et al. Dec 2010 A1
20100324359 Birk Dec 2010 A1
20110201874 Birk et al. Aug 2011 A1
Foreign Referenced Citations (120)
Number Date Country
949965 Jun 1974 CA
1250382 Apr 2000 CN
1367670 Sep 2002 CN
4225524 Feb 1994 DE
10020688 Dec 2000 DE
0119596 Sep 1984 EP
0230747 Aug 1987 EP
0416250 Mar 1991 EP
0611561 Aug 1994 EP
0695558 Feb 1996 EP
0876808 Nov 1998 EP
1036545 Sep 2000 EP
1072282 Jan 2001 EP
1105073 Jun 2001 EP
1396242 Mar 2004 EP
1396243 Mar 2004 EP
1491167 Dec 2004 EP
1491168 Dec 2004 EP
1529502 May 2005 EP
1547549 Jun 2005 EP
1574189 Sep 2005 EP
1600183 Nov 2005 EP
1602346 Dec 2005 EP
1704833 Sep 2006 EP
1719480 Nov 2006 EP
1736123 Dec 2006 EP
1736195 Dec 2006 EP
1736202 Dec 2006 EP
1743605 Jan 2007 EP
1829504 Sep 2007 EP
1829505 Sep 2007 EP
1829506 Sep 2007 EP
1967168 Sep 2008 EP
1992315 Nov 2008 EP
2074970 Jul 2009 EP
2074971 Jul 2009 EP
2074972 Jul 2009 EP
2095796 Sep 2009 EP
2095798 Sep 2009 EP
2191796 Jun 2010 EP
2688693 Sep 1993 FR
2769491 Apr 1999 FR
2783153 Mar 2000 FR
2797181 Feb 2001 FR
2799118 Apr 2001 FR
2823663 Oct 2002 FR
2921822 Apr 2009 FR
1174814 Dec 1969 GB
2090747 Jul 1982 GB
57-171676 Oct 1982 JP
2-019147 Jan 1990 JP
2-132104 Nov 1990 JP
11-244395 Sep 1999 JP
2003-526410 Sep 2003 JP
2005-131380 May 2005 JP
2005-334658 Dec 2005 JP
WO 8600079 Jan 1986 WO
WO 8600912 Feb 1986 WO
WO 8911701 Nov 1989 WO
WO 9000369 Jan 1990 WO
WO 9220349 Nov 1992 WO
WO 9402517 Feb 1994 WO
WO 9633751 Jan 1996 WO
WO 9835639 Aug 1998 WO
WO 9835640 Aug 1998 WO
WO 0000108 Jan 2000 WO
WO 0001428 Jan 2000 WO
WO 0009047 Feb 2000 WO
WO 0009049 Feb 2000 WO
WO 0015158 Mar 2000 WO
WO 0066196 Nov 2000 WO
WO 0110359 Feb 2001 WO
WO 0112078 Feb 2001 WO
WO 0141671 Jun 2001 WO
WO 0147435 Jul 2001 WO
WO 0147575 Jul 2001 WO
WO 0149245 Jul 2001 WO
WO 0152777 Jul 2001 WO
WO 0168007 Sep 2001 WO
WO 0185071 Nov 2001 WO
WO 0205753 Jan 2002 WO
WO 0209792 Feb 2002 WO
WO 0219953 Mar 2002 WO
WO 0226317 Apr 2002 WO
WO 0253093 Jul 2002 WO
WO 02065948 Aug 2002 WO
WO 02096326 Dec 2002 WO
WO 03007782 Jan 2003 WO
WO 03055420 Jul 2003 WO
WO 03057092 Jul 2003 WO
WO 03059215 Jul 2003 WO
WO 03077191 Sep 2003 WO
WO 03101352 Dec 2003 WO
WO 03105732 Dec 2003 WO
WO 2004014245 Feb 2004 WO
WO 2004019671 Mar 2004 WO
WO 2004108025 Dec 2004 WO
WO 2004112563 Dec 2004 WO
WO 2005007232 Jan 2005 WO
WO 2005009305 Feb 2005 WO
WO 2005067994 Jul 2005 WO
WO 2005072195 Aug 2005 WO
WO 2005087147 Sep 2005 WO
WO 2005094447 Oct 2005 WO
WO 2005112888 Dec 2005 WO
WO 2006040647 Apr 2006 WO
WO 2006049725 May 2006 WO
WO 2006083885 Aug 2006 WO
WO 2006108203 Oct 2006 WO
WO 2007067206 Jun 2007 WO
WO 2007081304 Jul 2007 WO
WO 2007106727 Sep 2007 WO
WO 2007114905 Oct 2007 WO
WO 2007145638 Dec 2007 WO
WO 2008063673 May 2008 WO
WO 2008134755 Nov 2008 WO
WO 2009050709 Apr 2009 WO
WO 2009132127 Oct 2009 WO
WO 2009136126 Nov 2009 WO
WO 2010042493 Apr 2010 WO
Non-Patent Literature Citations (87)
Entry
Brown et al; “Symmetrical Pouch Dilation After Laparoscopic Adjustable Gastric Banding: Incidence and Management”; Obesity Surgery; V. 18, pp. 1104-1108; 2008.
Ceelen et al.; “Surgical Treatment of Severe Obesity With a Low-Pressure Adjustable Gastric Band: Experimental Data and Clinical Results in 625 Patients”; Annals of Surgery; V. 237, No. 1; pp. 10-16; 2003.
Dixon et al.; “Pregnancy After Lap-Band Surgery: Management of the Band to Achieve Healthy Weight Outcomes”; Obesity Surgery; V. 11, pp. 59-65; 2001.
Neary et al.; “Peptide YY(3-36) and Glucagon-Like Peptide-1(7-36) Inhibit Food Intake Additively”; Endocrinology; V.146; pp. 5120-5127; 2005.
Padidela et al.; “Elevated basal and post-feed glucagon-like petide 1 (GLP-1) concentrations in the neonatel period”; European Journal of Endocrinology; v. 160; pp. 53-58; 2009.
Shi et al.; “Sexually Dimorphic Responses to Fat Loss After Caloric Restriction or Surgical Lipectomy”; Am. J. Physiol. Endocrinol. Metab.; V. 293; E316-E326; 2007.
Xanthakos et al.; “Bariatric Surgery for Extreme Adolescent Obesity: Indications, Outcomes, and Physiologic Effects on the Gut-Brain Axis”; Pathophysiology; V. 15; pp. 135-146; 2008.
Acuna-Goycolea et al.; “Mechanism of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Acruate Nucleus”; The Journal of Neuroscience; V. 25(32); pp. 7406-7419; Aug. 10, 2005.
Adrian et al.; “Mechanism of Pancreatic Polypeptide Release in Man.” The Lancet; pp. 161-163; Jan. 22, 1977.
Anson; “Shape Memory Alloys—Medical Applications,” Source: Materials World, vol. 7, No. 12, pp. 745-747, Dec. 1999.
Asakawa et al; “Antagonism of Ghrelin Receptor Reduces Food Intake and Body Weight Gain in Mice”; Gut.; V.52; pp. 947-952; 2003.
Baggio et al. “Biology of Incretins: GLP-1 and GIP”; Gastroenrology; V. 132; pp. 2131-2157; 2007.
Ballantyne; “Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release, and Actions”; Obesity Surgery; V.16; pp. 651-658; 2006.
Ballantyne; “Peptide YY(1-36) and Peptide YY(3-36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery”; Obesity Surgery; V.16; pp. 795-803; 2006.
Berne et al; “Physiology”; V. 5; pp. 55-57, 210, 428, 540, 554, 579, 584, 591; 2004.
BioEnterics Corporation, an Inamed Company, BioEnterics Intragastric Balloon; Directions for Use Published Document, P/N 94200 Rev: B, pp. 1-56.
BioEnterics Lap-Band Adjustable Gastric Banding System, Inamed Health, pub., pp. 1-115; Aug. 28, 2003.
Boulant et al.; “Cholecystokinin in Transient Lower Oesophageal Sphincter Relaxation Due to Gastric Distension in Humans”; Gut.; V. 40; pp. 575-581; 1997.
Bradjewin et al.; “Dose Ranging Study of the Effects of Cholecystokinin in Healthy Volunteers”; J. Psychiatr. Neurosci.; V. 16 (2); pp. 91-95; 1991.
Burdyga et al.; “Cholecystokinin Regulates Expression of Y2 Receptors in Vagal Afferent Neurons Serving the Stomach”; The Journal of Neuroscience; V. 28; No. 45; pp. 11583-11592; Nov. 5, 2008.
Chaptini et al.; “Neuroendocrine Regulation of Food Intake”; Current Opinion in Gastroenterology; V. 24; pp. 223-229; 2008.
Chaudhri; “Can Gut Hormones Control Appetite and Prevent Obesity?” Diabetes Care; V. 31; Supp 2; pp. S284-S289; Feb. 2008.
Cohen et al.; “Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans”; J. Clin. Endocrinol. Metab.; V. 88; No. 10; pp. 4696-4701; 2003.
Corno et al.; “A new implantable device for telemetric control of pulmonary blood flow”; New ideas; received Apr. 24, 2004; received in revised form Jul. 12, 2002; 10 pages.
Corno et al.; “FlowWatchTM in clipped and inclipped position”; Interact Cardio Vase Thorac Surg 2002; 1:46-49; Copyright @ 2002 The European Asociation for Cardio-thoracic Surgery; 1 page.
Cummings et al.; “Plasma Ghrelin Levels After Diet-Induced Weight Loss or Gastric Bypass Sugery”; N. Engl J. Med; V. 346, No. 21; pp. 1623-1630; May 23, 2002.
Cummings; “Gastrointestinal Regulation of Foot Intake”; The Food Journal of Clinical Investigation; V. 117, N. 1; pp. 13-23; Jan. 2007.
Dakin et al.; “Oxyntomodulin Inhibits Food Intake in the Rat”; Endocrinology; V. 142; No. 10; pp. 4244-4250; 2001.
Dakin et al.; “Peripheral Oxyntomodulin Reduces Food Intake and Body Weight gain in Rats”; Endocrinology; V. 145; No. 6; pp. 2687-2695; Jun. 2004.
Davison; “Activation of Vagal-Gastric Mechanoreceptors by Cholecystokinin”; Proc. West. Pharmocol. Soc.; V. 29; pp. 363-366; 1986.
De Waele et al.; “Endoscopic Volume Adjustment of Intragastric Balloons for Intolerance”; Obesity Surgery; V. 11; pp. 223-224; 2001.
De Waele et al.; “Intragastric Balloons for Preoperative Weight Reduction”; Obesity Surgery; V. 58; pp. 58-60; 2001.
Desai et al.; “Molecular Weight of Heparin Using 13C Nuclear Magnetic Resonance Spectroscopy” Journal of Pharmaceutical Science, V. 84, I 2; 1995, Abstract only.
Doldi et al.; “Intragastric Balloon: Another Option for Treatment of Obesity and Morbid Obesity”; Hepato-Gastroenterology; V. 51, N. 55; pp. 294-307; Jan.-Feb. 2004.
Doldi et al.; “Treatment of Morbid Obesity with Intragastric Balloon in Association with Diet”; Obesity Surgery; V. 10, pp. 583-587; 2000.
Doldi et al; “Intragastric Balloon in Obese Patients”; Obesity Surgery; V. 10, 578-581; 2000.
Ekblad et al.; “Distribution of Pancreatic Peptide and Peptide-YY”; Peptides; V. 23; pp. 251-261; 2002.
El Khoury et al.; “Variation in Postprandial Ghrelin Status Following Ingestion of High-Carbohydrate, High Fat, and High Protein Meals in Males”; Ann Nutr Metab; V. 50; pp. 260-269; 2006.
Galloro et al; “Preliminary Endoscopic Technical Report of an New Silicone Intragastric Balloon in the Treatment of Morbid Obesity”; Obesity Surgery; V. 9, pp. 68-71; 1999.
GinShiCel MH Hydroxy Propyl Methyl Cellulose, Web Page http://www.ginshicel.cn/MHPC.html, Nov. 12, 2008.
Girard; “The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiological functions”; Diabetes and Metabolism; V. 34; pp. 550-559; 2008.
Greenough et al.; “Untangling the Effects of Hunger, Anxiety, and Nausea on Energy Intake During Intravenous Cholecystokinin Octapeptide (CCK-8) Infusion”; Physiology & Behavior; V. 65, No. 2; pp. 303-310; 1998.
Grise et al.; “Peptide YY Inhibits Growth of Human Breast Cancer in Vitro and in Vivo”; Journal of Surgical Research; V. 82; pp. 151-155; 1999.
Grundy; “Signaling the State of the Digestive Tract”; Autonomic Neuroscience: Basic and Clinical; V. 125; pp. 76-80; 2006.
Grundy; “Vagal Control of Gastrointestinal Function”; Bailliere's Clinical Gastroenterology; V. 2; No. 1; pp. 23-43; 1988.
Hallden et al. “Evidence for a Role of the Gut Hormone PYY in the Regulation of Intestinal Fatty Acid Binding Protein Transcripts in Differentiated Subpopulations of Intestinal Epithelial Cell Hybrids”; Journal of Biological Chemistry; V. 272 (19); pp. 125916-126000; 1997.
Hameed et al.; “Gut hormones and appetite control.” Oral Diseases; V. 15; pp. 18-26; 2009.
Hassan et al.; “Effects of Adjuvants to Local Anesthetics on Their Duration III Experimental Studies of Hyaluronic Acid” Abstract Pub Med [Acta Anesthesiol Scand.; 29 (4): 384-8], 1 page; May 1985.
Hodson et al.; “Management of Obesity with the New Intragastric Balloon”; Obesity Surgery; V. 11, pp. 327-329, 2001.
Holzer; “Gastrointestinal Afferents as Targets of Novel Drugs for the Treatment of Functional Bowel Disorders and Visceral Pain”; European Journal of Pharmacology; V. 429; pp. 177-193; 2001.
Houpt; “Gastrointestinal Factors in Hunger and Satiety.” Neuroscience and Behavioral Reviews; V. 6; pp. 145-164; 1982.
Jones; “Molecular, pharmacological, and clinical aspects of liraglutide, a oncedaily human GLP-1 analogue”; Molecular and Cellular Endocrinology; V. 297; pp. 137-140; 2009.
Kerem et al.; “Exogenous Ghrelin Enhances Endocrine and Exocrine Regeneration in Pancreatectomized Rats”; J Gastrointest Surg.; V.13; pp. 775-783, 2009.
Kesty et al.; “Hormone-based therapies in the regulation of fuel metabolism and body weight”; Expert Opin. Biol. Ther.; V. 8; No. 11; pp. 1733-1747; 2008.
Kissileff et al.; “Peptides that Regulate Food Intake: Cholecystokinin and Stomach Distension Combine to Reduce Food Intake in Humans”; Am. J. Physiol. Regul. Integr. Comp. Physiol; V. 285; pp. 992-998; 2003.
Kojima et al.; “A role for pancreatic polypeptide in feeding and body weight regulation.” Peptides; V. 28; pp. 459-463; 2007.
Kulicke et al. “Visco-Elastic Propeerties of Sodium Hyaluronate Solutions,” American Institute of Physics; pp. 585-587; 2008.
Lap-Band AP System Adjustable Gastric Banding System With OmniformTM Design: Directions for Use (DFU); Allergan, 16 pages; 2009.
Le Roux et al.; “Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters”; Ann. Surg; V. 243; No. 1; pp. 108-114; Jan. 2006.
Liu et al.; “Adjuvant Hormonal Treatment With Peptide YY or Its Analog Decreases Human Pancreatic Carcinoma Growth”; The American Journal of Surgery; V. 171; pp. 192-196; Jan. 1996.
Mathus-Vliegen et al. “Intragastric Balloons for Morbid Obesity: Results, Patient Tolerance and Balloon Life Span”; Br. J. Surg.; V. 77, No. 7, pp. 76-79; Jan. 1990.
Mathus-Vliegen et al. “Treating Morbid and Supermorbid Obesity” International Journal of Gastroenterology; V. 5, No. 1, pp. 9-12; 2000.
Medeiros et al.; “Processing and metabolism of Peptide-YY: Pivotal roles of Dipeptidase-IV, Aminopeptidase-P, and Endopeptidase-24.11”; Endocrinology; V. 134, No. 5; pp. 2088-2094; 1994.
Naslund et al. “Pranidal subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects”; British Journal of Nutrition; V. 91; pp. 439-446; 2004.
Potier et al.; “Protein, amino acids, and the control of food intake”; Current Opinion in Clinical Nutrition and Metabolic Care; V. 12; pp. 54-58; 2009.
Qjan et al.; “Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117”; International Journal of Pharmaceutics; V. 366; pp. 218-220; 2008.
Rang et al.; “Pharmacology”; V. 5; pp. 203, 397, 402, 524; 2004.
Raybould et al.; “Integration of Postprandial Gastrointestinal Tract: Role of CCK and Sensory Pathways”; Annals of New York Academy of Science; pp. 143-156; 1994.
Renshaw et al. “Peptide YY: A Potential Therapy for Obesity”; Current Drug Targets; V. 6; pp. 171-179; 2005.
Sannino et al.; “Crosslinking of Cellulose Derivatives and Hyaluronic Acid with Water-Soluble Carbodiimide” Polymer 46; pp. 11206-11212; 2005.
Shechter et al.; “Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice”; FEBS Letters; V. 579; pp. 2439-2444; 2005.
Silver et al.; “Physical Properties of Hyaluronic Acid and Hydroxypropylmethylcellulose in Solution: Evaluation of Coating Abillity” Journal of Applied Biomaterials, V. 5; pp. 89-98, 1994.
Small et al.; “Gut hormones and the control of appetite”; Trends in Endocrinology and Metabolism; V. 15. No. 6; pp. 259-263; Aug. 2004.
Stanley et al.; “Gastrointestinal Satiety Signals III. Glucagon-like Peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide”; Am. J. Physiol Gastrointest Liver Physiol; V. 286; pp. 693-697; 2004.
Tezel; “The Science of Hyaluronic Acid Dermal Fillers,” Journal of Cosmetic and Laser Therapy (2008) 10: pp. 35-42.
Tolhurst et al.; “Nutritional regulation of glucagon-like peptidel secretion”; J. Physiol.; V. 587, No. 1; pp. 27-32; 2009.
Totte et al.; “Weight Reduction by Means of Intragastric Device: Experience with the Bioenterics Intragastric Balloon”; Obesity Surgery; V. 11, pp. 519-523; 2001.
Tough et al.; “Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa”; The Journal of Pharmacology and Experimental Therapeutics; V. 319, No. 1; pp. 20-30; 2006.
Tseng et al; “Peptide YY and cancer: Current findings and potential clinical applications”; Peptides; V. 23; pp. 389-395; 2002.
Valassi et al.; “Neuroendocrine control of food intake”; Nut. Metab. & Cariovasc. Disease; V. 18; pp. 158-168; 2008.
Van Der Lely et al.; “Biological, Physiological, Pathophysiological Aspects of Ghrelin”; Endocrine Reviews; V. 25, No. 3; pp. 426-457; 2004.
Verdich et al. “A Meta-Analysis of the Effect of Glucagon-Like-Peptide-1 (7-36) Amide on ad Libitum Energy Intake in Humans”; J. Clin. Endocrinal. Metab. V. 86; pp. 4382-4389; Sep. 2001.
Wahlen et al.; “The BioEnterics Intragastric Balloon (BIB): How to Use It”; Obesity Surgery; V. 11; pp. 524-527; 2001.
Wang et al.; “Plasma Ghrelin Modulation in Gastric Band Operation and Sleeve Gastrectomy”; Obes. Surg.; pp. 357-362; 2008.
Weiner et al.; “Preparation of Extremely Obese Patients for Laparoscopic Gastric Banding by Gastric Balloon Therapy”; Obesity Surgery; V. 9, pp. 261-264, 1999.
Wynne et al.; “Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind Randomized, Controlled Trial”; Diabetes; V. 54; pp. 2390-2395; 2005.
Yuzuriha et al.; “Gastrointestinal Hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development”; FASEB J.; V. 21; pp. 2108-2112; 2007.
Related Publications (1)
Number Date Country
20120215062 A1 Aug 2012 US
Continuations (2)
Number Date Country
Parent 12041547 Mar 2008 US
Child 13040204 US
Parent 10524864 US
Child 12041547 US